Auxilium Pharmaceuticals Inc

Type: Company
Name: Auxilium Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.auxilium.com/
First reported May 17 2013 - Updated May 17 2013 - 1 reports
Durata Therapeutics Inc
Durata Therapeutics Inc

Durata Therapeutics adds Dr Paul A Friedman to board

3 minutes ago, 7:48am (ET) 05/17/2013 M2Pharmaceutical company Durata Therapeutics (NasdaqGM:DRTX) revealed on Thursday the election of Dr Paul A Friedman MD to its board of directors at the 2013 Annual Meeting of Stockholders held today.Effective today, ... [Published Zecco - May 17 2013]
First reported May 16 2013 - Updated May 16 2013 - 1 reports

M&A activity focuses on broadening product pipelines in selected specialty markets

The Indian pharma sector witnessed no deals during April 2013 M&A activity in the pharmaceutical sector was focused on broadening product pipelines in selected specialty markets.In line with the above trend, Auxilium Pharmaceuticals acquired Actient Holdings, ... [Published Express Pharma - May 16 2013]
First reported May 16 2013 - Updated May 16 2013 - 1 reports

Curved penis treatment promising

When Tony Lee realised that his penis was curving whenever he had an erection - making it painful and difficult for him to have sex - he had no idea what was wrong. He became depressed and very worried, and his relationship with his wife started to c ... [Published Health24 - May 16 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports
UBS AG
UBS AG

Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference

CHESTERBROOK, Pa.(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on May 21, 2013. To access the live webcast, please log ... [Published Bio-Medicine - May 15 2013]
First reported May 13 2013 - Updated May 13 2013 - 1 reports

Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!CHESTERBROOK, Pa. , May 10, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive... ... [Published BioSpace - May 13 2013]
First reported May 07 2013 - Updated May 08 2013 - 2 reports
GTCR Golder Rauner
GTCR Golder Rauner

GTCR Announces Sale of Actient to Auxilium Pharmaceuticals

By a News Reporter-Staff News Editor at Biotech Week -- GTCR, a leading private equity firm, announced it has sold its portfolio company, Actient Holdings LLC ("Actient"), to Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL, "Auxilium"), a specialty biopharmaceutical ... [Published Equities.com - May 08 2013]
First reported May 01 2013 - Updated May 01 2013 - 2 reports
Auxilium Pharmaceuticals Inc
Auxilium Pharmaceuticals Inc

Possible Bullish Inside Day Candle Pattern Detected for Auxilium Pharmaceuticals (NASDAQ:AUXL)

(Financial News Network On) Analyzing the price chart for Auxilium Pharmaceuticals (NASDAQ:AUXL) has revealed a potential bullish inside day candle pattern. Yesterday's price range of $14.15 and $15.01 is within the prior day's high and low of the day. ... [Published Individual.com - May 01 2013]
First reported Apr 30 2013 - Updated Apr 30 2013 - 2 reports

Auxilium Pharma Price Target Cut to $20.00 (AUXL)

Analysts at Canaccord Genuity decreased their price target on shares of Auxilium Pharma (NASDAQ: AUXL)Other equities research analysts have also recently issued reports about the stock. Analysts at MKM Partners cut their price target on shares of Auxilium ... [Published American Banking News - Stock Ratings - Apr 30 2013]
First reported Apr 30 2013 - Updated Apr 30 2013 - 2 reports

Stifel Nicolaus Upgrades Auxilium Pharmaceuticals (AUXL) to Buy

Stifel Nicolaus upgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Hold to Buy.For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here. Shares of Auxilium ... [Published Street Insider - Apr 30 2013]
First reported Apr 29 2013 - Updated Apr 30 2013 - 11 reports

Auxilium Pharma acquires urology specialty therapeutics co, Actient Holdings

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, has completed the acquisition of Actient Holdings LLC (Actient), a private urology specialty therapeutics company, for $585 million in upfront cash plus certain contingent consideration ... [Published PharmaBiz - Apr 30 2013]
First reported Apr 29 2013 - Updated Apr 30 2013 - 2 reports

Auxilium Pharmaceuticals, Inc. (AUXL) Misses Q1 EPS by 7c

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) reported Q1 EPS of ($0.05), $0.07 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $66.2 million versus the consensus estimate of $81.23 million.For earnings history and earnings-related ... [Published Street Insider - Apr 29 2013]
First reported Apr 29 2013 - Updated Apr 29 2013 - 2 reports

Shares of Auxilium Pharmaceuticals Under Pressure, Down 7.7%

Auxilium Pharmaceuticals (NASDAQ:AUXL) is one of today's notable stocks in decline, down 7.7% to $14.79. The S&P is currently trading 0.5% higher to 1,590 and the Dow Jones Industrial Average is trading 0.4% higher to 14,768.Auxilium Pharmaceuticals is ... [Published Comtex SmarTrend - Apr 29 2013]

Quotes

...drug candidates from discovery through development to successful commercialization," said Richard De Schutter, Durata's Chairman of the Board. "We would also like to thank Dov for his many contributions and his commitment to Durata."
Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of Directors [Published Individual.com - May 16 2013]
Lee encouraged people to involve their partners to help them deal with the disease. "If there is a significant other in your life, you guys need to come togethertogether with this. For me, that made all the difference."
Curved penis treatment promising [Published Health24 - May 16 2013]
"We are very pleased to have completed enrollment in our Phase II trials in canine and human lipoma and we remain on track to report top-line data for both trials in the second half of this year" reflected Thomas L Wegman, President of BioSpecifics. $ First Quarter 2013 Financial Results
BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results PR Newswire [Published Yahoo! Finance - May 10 2013]
...we remain on track to report top-line data for both trials in the second half of this year," reflected Thomas L Wegman, President of BioSpecifics. "In addition, there are a number of exciting upcoming milestones for XIAFLEX this year. We are looking forward to the potential approval of XIAFLEX for the treatment of Peyronie's Disease in the third quarter of this year and if approved, we would anticipate the U S commercial launch in this indication in the fourth quarter of 2013. We are also eagerly awaiting the initiation of a new clinical trial for XIAFLEX in frozen shoulder syndrome in the second half of this year, following the announcement of the statistically significant top-line data from the Phase IIa study, as well as the initiation of a Phase II study in the cellulite indication during the same time period. Finally we believe there is tremendous potential for XIAFLEX in the treatment of many medical conditions caused by excess collagen accumulation and BioSpecifics will continue to devote its efforts to the development in new clinical indications in the future."
BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results [Published Staten Island Live - May 10 2013]

More Content

All (182) | News (133) | Reports (6) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (31)
sort by: Date | Relevance
Post Earnings Update: Auxilium Pharmaceuticals ... [Published Individual.com - May 18 2013]
Aridis Pharma Picks Up Kenta Biotechs Anti-Infe... [Published Mergers & Acquisitions - May 17 2013]
Durata Therapeutics adds Dr Paul A Friedman to ... [Published Zecco - May 17 2013]
Paul A. Friedman, M.D. is Elected to Durata The... [Published Individual.com - May 16 2013]
M&A activity focuses on broadening product pipe... [Published Express Pharma - May 16 2013]
Curved penis treatment promising [Published Health24 - May 16 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published Bio-Medicine - May 15 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published PR Newswire: General Business - May 15 2013]
[Auxilium] buys [Actient Pharmaceuticals] from ... [Published BioPortfolio - May 14 2013]
Auxilium Pharmaceuticals to Present at the Bank... [Published BioSpace - May 13 2013]
Auxilium Pharma Price Target Cut to $31.00 by A... [Published American Banking News - May 12 2013]
Auxilium Pharmaceuticals has the Best... [Published Financial News Network online - May 12 2013]
Form SC 13G/A AUXILIUM PHARMACEUTICALS Filed by... [Published Street Insider - May 10 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published Bio-Medicine - May 10 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published PR Newswire - May 10 2013]
Buyers Accumulate Shares of Auxilium Pharmaceut... [Published Individual.com - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Yahoo! Finance - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published ADVFN UK - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Staten Island Live - May 10 2013]
Tesoro Corporation (TSO), Krispy Kreme Doughtnu... [Published InsiderMonkey.com - May 08 2013]
Fifth Street Enters ABL Market Through $110M Ac... [Published Mergers & Acquisitions - May 08 2013]
GTCR Announces Sale of Actient to Auxilium Phar... [Published Equities.com - May 08 2013]
Auxilium Pharmaceuticals Q1 net loss widens [Published Individual.com - May 08 2013]
Sell in May, But Don't Go Away [Published Motley Fool - May 08 2013]
High Response to Enzyme in Peyronie's [Published MedPage Today - May 08 2013]
Treatment for Painful Curved Penis Shows Promise [Published WebMD - May 08 2013]
Treatment for Painful Curved Penis Shows Promise [Published WebMD - May 08 2013]
Treatment for Painful Curved Penis Shows Promise [Published Health Finder - May 08 2013]
Auxilium Pharmaceuticals Inc to acquire Actient... [Published International Law Office - May 07 2013]
Auxilium Pharmaceuticals In Retrospect: Shares ... [Published Individual.com - May 07 2013]
1 2 3 4 5 6 7
In Focus
  •  
Adrian Adams, Thomas Wei, Tony Lee, [more]
  •  
GTCR Golder Rauner, BioSpecifics Technologies Corp, Stifel Nicolaus, [more]
  •  
European Union, FDA Food & Drug Administration, Baylor College of Medicine, [more]
  •  
8-k, Healthcare Conference, Health Care, [more]
  •  
Xiaflex, Xignite Financials, iPad, [more]
  •  
Chesterbrook (United States), Lake Forest (Illinois, United States), Chicago, [more]
  •  
United States, Canada, Japan, [more]
  •  
Financial Reporting, Mergers & Acquisitions, Biotechnology, [more]
  •  
Pharma & Biotech, Health, Banking & Financial Services, [more]
SEC Filings, Individual.com, PR Newswire: Health, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013]
In the first half of 2013, two drugs will have launched in the US priced at $250,000 per patient annually: Both address serious, ultra-rare diseases and are backed by KOLs and patients. But the similarities stop there. Three months into its launch, ...
Best Buy Is a Buy and 3 More Analyst Upgrades T... [Published Wall St. Cheat Sheet - Apr 30 2013]
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...
The Morning Leverage: A Testosterone-Fueled Exi... [Published WSJ.com: Private Equity Beat - Apr 30 2013]
Mike Lucas for Dow Jones Top stories in this morning’s LBO Wire: As the recent plethora of commercials for treatments of “low T” might suggest, the market for testosterone therapies is booming. GTCR has taken advantage of the trend with the $585 million ...
Auxilium Pharmaceuticals Earnings: Here’s Why t... [Published Wall St. Cheat Sheet - Apr 29 2013]
Auxilium Pharmaceuticals Inc. ( NASDAQ:AUXL ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are ...
Auxilium Pharmaceuticals Earnings: Here’s Why t... [Published Wall St. Cheat Sheet - Apr 29 2013]
Auxilium Pharmaceuticals Inc. ( NASDAQ:AUXL ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares ...
1 2 3

Press Releases

sort by: Date | Relevance
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published PR Newswire: General Business - May 15 2013]
Auxilium Pharmaceuticals, Inc. To Present At Th... [Published PR Newswire - May 10 2013]
GTCR Announces Sale of Actient to Auxilium Phar... [Published Business Wire - Apr 29 2013]
GTCR Announces Sale of Actient to Auxilium Phar... [Published Business Wire Professional Services News - Apr 29 2013]
GTCR Announces Sale of Actient to Auxilium Phar... [Published Business Wire Health News - Apr 29 2013]
1 2 3 4 5 6 7
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.